Leah Sherwood

Blood Cancers Today

The US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for P-CD19CD20-ALLO1, an allogeneic dual chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies.The CAR-T targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies. It will be evaluated for safety, tolerability, and preliminary efficacy in a phase I multicenter, open-label, dose-escalation study, which will enroll up to 70 patients. After enrollment, patients will receive a chemotherapy-based lymphodepletion regimen followed by administration of the product.Source: PR Newswire, July 2023&nbsp;&nbsp;

FDA Clears IND Application for P-CD19CD20-ALLO1

The latest news, research, and perspectives in aggressive B-cell lymphoma. These fast-growing non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma, arise at different stages of B-cell development.

Aggressive B-Cell Lymphoma

P-CD19CD20-ALLO1 targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies.

Editorial Board

About Us

Terms of Use

Advertising

Privacy Policy

Editorial Policy

MashupMD

GU Oncology Now

Cancer Nursing Today

Urban Health Today

DocWire News

eNewsletters

Calendar of Events

Contact Us

Contribute

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

Leukemia

Hodgkin Lymphoma

Indolent B-Cell Lymphoma

Mantle Cell Lymphoma

T-Cell Lymphoma

Lymphoma

Myelofibrosis

Polycythemia Vera

Myeloma

Transplantation & Cellular Therapy

The HemOnc Pulse

Meeting News

The HemOnc Pulse Live

Video Insights

In Print

Subscribe